GT BIOPHARMA INC news, videos and press releases
For more news please use our advanced search feature.
GT BIOPHARMA INC - More news...
GT BIOPHARMA INC - More news...
- GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
- GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies
- GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September
- GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
- GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
- GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
- GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update
- GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
- GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors
- GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer
- GT Biopharma Announces Former Abraxis CEO, Bruce J. Wendel as Vice Chairman of GTBP Board of Directors
- GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting
- GT Biopharma Announces Publication of Trike(TM) Results Targeting Multiple B7H3 Positive Cancers
- GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting
- GT Biopharma Announces Advisory Board Appointments
- GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics
- GT Biopharma Announces GTB-3550 TriKE(TM) Phase I/II Clinical Trial Update
- GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
- GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
- GT Biopharma Announces Completion of $5.6 Million Bridge Financing
- GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
- GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy
- GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills
- GT Biopharma Announces HIV Trike™ Data to be Published